Moving forward in clinical research with master protocols

With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jay J.H., Dron, Louis, Mills, Edward J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120789/
https://www.ncbi.nlm.nih.gov/pubmed/34000408
http://dx.doi.org/10.1016/j.cct.2021.106438
_version_ 1783692175046868992
author Park, Jay J.H.
Dron, Louis
Mills, Edward J.
author_facet Park, Jay J.H.
Dron, Louis
Mills, Edward J.
author_sort Park, Jay J.H.
collection PubMed
description With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.
format Online
Article
Text
id pubmed-8120789
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-81207892021-05-14 Moving forward in clinical research with master protocols Park, Jay J.H. Dron, Louis Mills, Edward J. Contemp Clin Trials Short Communication With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19. Elsevier Inc. 2021-07 2021-05-14 /pmc/articles/PMC8120789/ /pubmed/34000408 http://dx.doi.org/10.1016/j.cct.2021.106438 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Park, Jay J.H.
Dron, Louis
Mills, Edward J.
Moving forward in clinical research with master protocols
title Moving forward in clinical research with master protocols
title_full Moving forward in clinical research with master protocols
title_fullStr Moving forward in clinical research with master protocols
title_full_unstemmed Moving forward in clinical research with master protocols
title_short Moving forward in clinical research with master protocols
title_sort moving forward in clinical research with master protocols
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120789/
https://www.ncbi.nlm.nih.gov/pubmed/34000408
http://dx.doi.org/10.1016/j.cct.2021.106438
work_keys_str_mv AT parkjayjh movingforwardinclinicalresearchwithmasterprotocols
AT dronlouis movingforwardinclinicalresearchwithmasterprotocols
AT millsedwardj movingforwardinclinicalresearchwithmasterprotocols

Ejemplares similares